The high level of genetic diversity between individual tumors suggests that if it were to be developed, a broad cancer vaccine would be unlikely to work for more than 0.3 percent of the population, according to new research.
The high level of genetic diversity between individual tumors suggests that if it were to be developed, a broad cancer vaccine would be unlikely to work for more than 0.3 percent of the population, according to new research.